Company anticipates sharing topline data and completing regulatory submissions in 2018
GAITHERSBURG, Md., March 15, 2017 /PRNewswire/ -- Vtesse, Inc. announced today that its registrational study of investigational drug VTS-270 in Niemann-Pick Type C1 disease (NPC) is fully enrolled.
$51.7 million financing broadens investor base and provides flexibility to advance clinical stage potentiator program and expand antibacterial pipeline
CAMBRIDGE, Mass, March 8, 2017 – Spero Therapeutics, LLC, a biopharmaceutical company founded to develop novel therapies to treat bacterial infections, announced today that it has completed a $51.7 million Series C preferred financing led by new investor GV (formerly Google Ventures). The round includes participation by additional new investors RA Capital Management and Rock Springs Capital as well as existing investors.
Cambridge, UK, February 20 2017 – VHsquared, the oral domain antibody company, is pleased to announce that the first patients have entered the international Phase II trial of its lead product, V565, in Crohn's disease. The aim of the HARBOR study1 is to show the efficacy of the anti-TNFα oral domain antibody as measured by changes in clinical symptoms, markers of inflammation and endoscopic appearance. It is randomised, doubleblind and placebo-controlled, involving over 100 patients with moderately to severely active Crohn’s disease. VHsquared is developing a portfolio of complementary oral domain antibodies (Vorabodies) which engage validated biological targets with the potential to transform the treatment of inflammatory bowel disease (IBD).
Extensive Phase 3 programme demonstrates clinical potential of BAREMSIS in rescue treatment and prophylaxis of PONV – NDA to be submitted to the US FDA 1H 2017
Cambridge, UK – 13th February 2017: Acacia Pharma Group Ltd (“Acacia Pharma”), the supportive care company developing products for US and international markets, announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis.
a Phase IIb Study for the Treatment of Cardiovascular Calcification in End-Stage-Renal-Disease Patients on Haemodialisis.
San Diego, USA and Palma, Spain, January 23, 2016 - Laboratoris Sanifit S.L., a clinical-stage biopharmaceutical company focused on treatments for calcification disorders, today announced that the first patient has been enrolled in the Phase IIb “CaLIPSO Study” clinical trial of lead candidate, SNF472, for the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease (ESRD) patients on haemodialysis (HD).
Clinicians Continuing to Enroll Children with NPC at Trial Sites in the United States, Germany, the United Kingdom, France, Spain, and Turkey
GAITHERSBURG, Md., Jan. 10, 2017 /PRNewswire/ -- Vtesse, Inc., a company committed to developing medicines to benefit patients with ultra rare, life-threatening diseases, announced today that clinicians have dosed the first trial participants in Australia in the company's global, pivotal clinical trial of investigational drug VTS-270 for Niemann-Pick Type C1 disease (NPC).
Funding supports preparation for commercial introduction of Furoscix™ and further advancement of the sc2Wear™ drug delivery platform.
LEXINGTON, Mass., Jan. 4, 2017 /PRNewswire/ -- scPharmaceuticals, Inc., a privately held biopharmaceutical company developing transformative pharmaceutical products for subcutaneous delivery announced today that it has closed a $45.6 million Series B investment round. The investment was co-led by OrbiMed and a wholly-owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma). In addition to OrbiMed and Sun Pharma, existing investors 5AM Ventures and Lundbeckfond Ventures participated in the financing. This Series B investment will support the development of the operational and commercial infrastructure to bring Furoscix™ and the sc2Wear™ Infusor to market in the United States.
|1 2 3 4 5 6 7 8 9 10 Næste 10 Næste|